News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website


Novogen up 13% premarket on positive brain cancer study results

Al's Comment:

Sounds promising. It hasn't been tried in humans yet but the key here is that it preferentially kills tumor cells over normal brain cells, at least in the test tube.

Posted on: 05/11/2015

Novogen up 13% premarket on positive brain cancer study results

  • Nano cap Novogen (NASDAQ:NVGN) jumps 13% premarket on increased volume in response to its announcement that its experimental cancer drug candidate, TRXE-009, demonstrated the ability to kill cancer cells from pediatric patients with an incurable form of brain cancer called diffuse intrinsic pontine glioma (DIPG). Patients with DIPG have poor prognoses with a median survival of less than one year. Its diffuse nature precludes the use of surgery, radiation only provides temporary relief and chemotherapy shows no benefit.
  • In patient-derived cell cultures, TRXE-009 killed DIPG cells at therapeutically relevant concentrations by inducing a type of programmed cell death calledcaspase-dependent apoptosis. Normal brain cells called astrocytes were only affected at much higher concentrations of TRXE-009 indicating an encouraging therapeutic index.
  • The data were presented at the 3rd Biennial Conference on Pediatric Neuro-Oncology Basic and Translational Research in San Diego, May 7-8.
  • TRXE-009 is a pan-acting anti-cancer cytotoxic molecule in a family called super-benzopyrans. Its precise mechanism of action is unknown but it induces cell death in cancer cells with stem cell-like activity.


Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557